John M. Evans, CEO at Beam Therapeutics Inc. (BEAM), sold 38,300 shares at $97.50 ($3.8M) on 2021-08-19, disclosed to the SEC on 2021-08-20.
Open-market sale of $3.8M BEAM by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $96.38 | 400 | $39K | 1.0% |
| 2 | $97.50 | 1,000 | $98K | 2.6% |
| 3 | $98.74 | 3,140 | $310K | 8.1% |
| 4 | $98.74 | 3,140 | $310K | 8.1% |
| 5 | $99.53 | 9,704 | $966K | 25.3% |
| 6 | $99.53 | 9,704 |
| $966K |
| 25.3% |
| 7 | $100.35 | 5,456 | $548K | 14.4% |
| 8 | $100.35 | 5,456 | $548K | 14.4% |
| 9 | $101.00 | 300 | $30K | 0.8% |
| Total | $99.56 avg | 38,300 | $3.8M | 100% |
| Filing → |
| BEAM | SELL | 2026-04-01 | $1.1M | — | Filing → |
| BEAM | SELL | 2026-02-02 | $2.8M | — | Filing → |
| BEAM | SELL | 2025-10-03 | $1.2M | — | Filing → |